Published: Sun, January 14, 2018
Business | By Tara Barton

Exact Sciences Corporation (EXAS)

Lake Street Capital cut their price objective on shares of Exact Sciences Corp. from $15.00 to $8.00 and set a "hold" rating for the company in a research report on Tuesday, November 1st. Over the past five trading sessions it is -1.92%; 5.97% for the month; 12.57% for the last quarter; 41.98% for the past six-months; and 195.07% for the last 12 months. About 4.70 million shares traded or 157.50% up from the average.

Current levels places Exact Sciences Corporation (NASDAQ:EXAS)'s stock about -17.26% from the 50-day high and 8.83% away from the 50-day low. It has outperformed by 441.54% the S&P500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Ardevora Asset Management Llp sold 37,500 shares as the company's stock rose 4.66% with the market. Us Savings Bank De reported 730,669 shares stake. E&G Advisors Lp who had been investing in Citigroup Inc for a number of months, seems to be less bullish one the $203.17 billion market cap company. The stock increased 1.09% or $1.01 during the last trading session, reaching $94.07.

In related news, insider Kevin T. Conroy sold 134,057 shares of EXACT Sciences stock in a transaction on Tuesday, November 21st. Citigroup Inc. (NYSE:C) has risen 35.60% since January 13, 2017 and is uptrending. It has outperformed by 56.14% the S&P500.

On average, analysts expect that EXACT Sciences will report full-year sales of $76.55 million for the current financial year, with estimates ranging from $236.73 million to $258.51 million. Therefore 56% are positive. Leerink Swann reissued an "outperform" rating and set a $67.00 price objective (up from $63.00) on shares of EXACT Sciences in a report on Monday, November 13th. 2017, Exact Sciences Corporation (EXAS) delivered a 11.63% surprise with its net revenue. The stock now has a consensus rating of "Buy" and an average target price of $50.58. The stock has a market cap of $6,590.00, a PE ratio of -47.88 and a beta of 0.68. (NYSE:C) on Sunday, July 16 with "Buy" rating. The firm earned "Buy" rating on Wednesday, May 31 by Roth Capital. The rating was maintained by Empire with "Sell" on Friday, February 26. Its down 0.26, from 1.27 in 2017Q2.

A number of other institutional investors have also recently bought and sold shares of EXAS. 44 funds opened positions while 77 raised stakes. Gofen And Glossberg Ltd Liability Il invested 0.02% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). 81,025 Exact Sciences Corporation (NASDAQ:EXAS) shares with value of $3.82 million were sold by LIDGARD GRAHAM PETER. Reynders Mcveigh Cap Mgmt Llc holds 0.42% or 94,722 shares in its portfolio. Jennison Assoc Llc owns 3.02 million shares or 0.22% of their USA portfolio. Sandy Spring Bank & Trust invested 0.02% in Exact Sciences Corporation (NASDAQ:EXAS). The New York-based Jennison Assocs Limited Liability Company has invested 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Tiaa Cref Limited Liability Corp owns 330,288 shares. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company's stock valued at $334,589,000 after buying an additional 700,051 shares during the period. Next Century Growth Limited Liability Co has invested 0.94% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS).

Kinder Morgan (KMI) Earns Outperform Rating from Analysts at Credit Suisse Group
Susquehanna Intll Grp Limited Liability Partnership owns 2.00 million shares or 0.02% of their USA portfolio. (NYSEAMERICAN:LBY). The investment professionals in our partner's database now possess: 1.31 billion shares, up from 1.27 billion shares in 2017Q2.

Since September 1, 2017, it had 0 insider purchases, and 5 insider sales for $10.27 million activity.

Green Valley Investors Llc decreased Unitedhealth Group Inc (NYSE:UNH) stake by 12,506 shares to 442,762 valued at $86.72 million in 2017Q3. LLC increased its stake in EXACT Sciences by 59.1% during the second quarter. $13.84 million worth of The Boeing Company (NYSE:BA) was sold by Muilenburg Dennis A on Monday, July 31. The target implies a 7.34% spike from where the shares are now trading. WALSH JEFFREY R sold 5,000 shares worth $344,870. Smith Gregory D had sold 19,757 shares worth $4.85 million.

The company's consensus rating on Reuter's scale remained unchanged from 1.92 to 1.92 during a month. Citigroup Inc. had 108 analyst reports since July 21, 2015 according to SRatingsIntel. The company maintains price to book ratio of 12.24 industry average at 26.34. The company was downgraded on Wednesday, April 20 by Bank of America. The firm has "Neutral" rating given on Monday, November 13 by Robert W. Baird. The firm has "Buy" rating given on Wednesday, June 7 by Canaccord Genuity. Paradigm Financial Advisors Llc bought 59,122 shares as the company's stock declined 7.50% while stock markets rallied. C Group Inc Holding A S, a Denmark-based fund reported 153,130 shares. The company was upgraded on Thursday, July 27 by Credit Suisse. Jefferies maintained the shares of BA in report on Wednesday, July 5 with "Buy" rating. The stock recovered 224.84% since its low point and has performed 4.8% year-to-date.

Nicholas Investment Partners Lp, which manages about $1.37 billion and $1.45 billion US Long portfolio, decreased its stake in Biomarin Pharmaceutical Inc (Prn) by 1.90M shares to 7.01 million shares, valued at $8.39 million in 2017Q3, according to the filing. It also increased its holding in Burlington Stores Inc (NYSE:BURL) by 38,100 shares in the quarter, for a total of 440,700 shares, and has risen its stake in Illinois Tool Wks Inc (NYSE:ITW). The average analysts gave this company a mean recommendation of 3.00. During the same period previous year, the company earned ($0.36) earnings per share.

Like this: